KetaMoHydBup: Pharmacokinetic Interaction of S-ketamine, Morphine, Hydromorphone and Buprenorphine
- Conditions
- The Effect of S-ketamine on Pharmacokinetics of Morphine, Hydromorphone, and Buprenorphine
- Interventions
- Registration Number
- NCT05571176
- Lead Sponsor
- Elina Brinck
- Brief Summary
S-ketamine is often administered as a part of multimodal analgesia to reduce postoperative pain and postoperative opioid consumption. Current data indicates that ketamine may be useful for patients with prior use of opioids whereas the benefit for opioid-naive patients is less clear. However, different opioids have variable pharmacokinetic characteristics. Therefore, it is important to evaluate S-ketamine's effect on the pharmacokinetics of opioids.
- Detailed Description
S-ketamine is often used as a part of multimodal analgesia to reduce postoperative pain and opioid consumption, in part by mitigating opioid tolerance and opioid-induced hyperalgesia. However, there are mixed results concerning the effect of ketamine for this indication. Different opioids have various pharmacokinetic characteristics. Ketamine is known to inhibit the liver UGT2B7-enzyme, that is responsible for e.g., morphine metabolism. Therefore, it is important to investigate whether there is a clinically important pharmacokinetic interaction between S-ketamine and opioids metabolized via liver UGT2B7 enzyme. These opioids include morphpine, hydromorphone and buprenoprhine.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 12
- written informed consent
- age 18-45 years
- healthy
- Normal values in the following laboratory assessments: Hb, P-ALAT, P-AFOS, P-GT, P-creatinine, P-K, P-Na, chemical sample for urine (U-KemSeul). Pregnancy test (P-hCG-tot) must be negative.
- Urine sample for detection of any illegal drugs must be negative (U-Huum-PS)
- Normal EKG
- Normal blood pressure
- No prior use of illicit drugs
- Tendency/predisposition to illicit drug use, illicit drug use in history
- Abnormal EKG
- smoking
- use of oral contraceptives
- pregnancy, lactation
- participating in a less tha 3 months ago
- Blood donation less than 3 months ago
- The subject's peripheral veins are hardly visible (predisposing difficulties in cannulation)
- weight less than 50 kg, body mass index (BMI) less than 18,5 or over 30
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description S-ketamine infusion S-ketamine 12 healthy volunteers, S-ketamine infusion 0.29 mg/kg/h for 4 hours Placebo (NaCl 0.9%) infusion S-ketamine 12 healthy volunteers, placebo (NaCl 0.9%) infusion for 4 hours
- Primary Outcome Measures
Name Time Method Area under the plasma concentration versus time curve (AUC) of morphine, hydromorphone and buprenorphine after intravenous S-ketamine infusion. Time points for the measurements after the initiation of S-ketamine infusion: 0 minutes, 60 minutes, 90 minutes, 120 minutes, 180 minutes and 210 minutes We aim to investigate whether there is a clinically significant pharmacokinetic interaction between S-ketamine and morphine, S-ketamine and hydromorphone and S-ketamine and buprenorphine.
Half-life time (t1/2) of morphine, hydromorphone and buprenorphine concentrations after intravenous S-ketamine infusion. Time points for assessing half-life time of morphine, hydromorphone and buprenorphine are 0 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 180 minutes and 210 minutes after initiation of S-ketamine infusion. We aim to investigate whether there is a clinically significant pharmacokinetic interaction between S-ketamine, morphine, S-ketamine and hydromorphone and S-ketamine and buprenorphine.
Peak plasma concentrations (Cmax) of morphine, hydromorphone and buprenorphine after intravenous S-ketamine infusion Time points for assessing peak plasma concentrations (Cmax) for morphine, hydromorphone and buprenorphine are the following: 0 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, 180 minutes, 210 minutes after the initiation of S-ketamine infusion. We aim to investigate whether there is a clinically significant pharmacokinetic interaction between S-ketamine, morphine, S-ketamine and hydromorphone and S-ketamine and buprenorphine.
- Secondary Outcome Measures
Name Time Method The effect of S-ketamine infusion on cortisol release. Time points for assessments: 30 minutes, 120 minutes, 240 minutes, 360 minutes, 480 minutes and at Day1 after the intiation of S-ketamine infusion We measure cortisol levels (nmol/l) during and after intravenous S-ketamine infusion.
The effect of S-ketamine on brain-derived neurotrophic factor (BDNF) release Time points for assessments: 30 minutes, 120 minutes, 240 minutes, 360 minutes, 480 minutes and at Day1 after the intiation of S-ketamine infusion We measure BDNF plasma levels (ng/ml) during and after intravenous S-ketamine infusion .
The effect of S-ketamine infusion on prolactin release. Time points for assessments: 30 minutes, 120 minutes, 240 minutes, 360 minutes, 480 minutes and at Day1 after the intiation of S-ketamine infusion We measure prolactin levels (mU/l) during and after intravenous S-ketamine infusion.
The effect of S-ketamine on vascular endothelial growth factor (VEGF) release Time points for assessments: 30 minutes, 120 minutes, 240 minutes, 360 minutes, 480 minutes and at Day1 after the intiation of S-ketamine infusion. We measure VEGF levels (ng/l) during and after intravenous S-ketamine infusion.
The effect of S-ketamine infusion on thrombocyte aggregation. At 2 hours after initiation of S-ketamine infusion. We evaluate the effect of intravenous S-ketamine infusion on thrombocyte aggregation by using Platelet Function Analyzer (PFA), a method that is based on the property of platelets to adhere upon shear stress conditions and aggregate in consequence of agonist presence in the system. We assess the clotting time. Unit of analysis is seconds (s).